(Q33166813)

23 July 2017

Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials (English)

1 reference

23 July 2017

Kristina Johnsson

1

1 reference

23 July 2017

Eva Johnsson

2

1 reference

23 July 2017

Traci A Mansfield

3

1 reference

23 July 2017

Yshai Yavin

4

1 reference

23 July 2017

Agata Ptaszynska

5

1 reference

23 July 2017

Shamik J Parikh

6

1 reference

23 July 2017

language of work or name

English

0 references

publication date

15 February 2016

1 reference

23 July 2017

Postgraduate Medicine

1 reference

23 July 2017

128

1 reference

23 July 2017

4

1 reference

23 July 2017

346-355

1 reference

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

23 July 2017

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Orthostatic hypotension in the elderly: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Blood urea nitrogen and serum creatinine. Physiology and interpretations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Short commentary on empagliflozin and its potential clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

Effects of Diuretics on Outputs and Flows of Urine and Urinary Solutes in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1153941

10.1080/00325481.2016.1153941

21 January 2018

Identifiers

DOI

1 reference

23 July 2017

1 reference